Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$10.37 -0.3%	$9.37	$5.92 ▼ $11.31	$2.17B	1.11	3.04 million shs	2.66 million shs
DVAX Dynavax Technologies	$10.27 -1.3%	$10.47	$9.22 ▼ $14.63	$1.23B	1.07	2.20 million shs	1.12 million shs
FOLD Amicus Therapeutics	$6.03 -2.3%	$6.48	$5.81 ▼ $12.65	$1.86B	0.54	2.98 million shs	4.22 million shs
LGND Ligand Pharmaceuticals	$112.50 -1.7%	$105.48	$77.53 ▼ $129.90	$2.17B	0.83	116,482 shs	83,330 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	-0.29%	-6.07%	+5.28%	+34.68%	+64.60%
DVAX Dynavax Technologies	-1.25%	+0.29%	+9.26%	-25.96%	-15.12%
FOLD Amicus Therapeutics	-2.27%	-2.11%	+2.55%	-32.25%	-43.33%
LGND Ligand Pharmaceuticals	-1.70%	+6.14%	+7.05%	+5.94%	+40.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCRX BioCryst Pharmaceuticals	4.4084 of 5 stars	4.4	1.0	4.2	3.4	1.7	0.6
DVAX Dynavax Technologies	4.1195 of 5 stars	3.3	1.0	4.7	2.0	1.7	1.9
FOLD Amicus Therapeutics	4.0675 of 5 stars	3.4	2.0	4.3	2.3	0.0	1.9
LGND Ligand Pharmaceuticals	4.3929 of 5 stars	3.5	0.0	4.4	2.6	3.3	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCRX BioCryst Pharmaceuticals	2.89	Moderate Buy	$16.56	59.65% Upside
DVAX Dynavax Technologies	2.50	Moderate Buy	$24.00	133.69% Upside
FOLD Amicus Therapeutics	2.70	Moderate Buy	$16.22	169.03% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$146.14	29.90% Upside

Current Analyst Ratings Breakdown

Latest DVAX, BCRX, LGND, and FOLD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	LGND Ligand Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$142.00 ➝ $145.00
5/7/2025	BCRX BioCryst Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $11.00
5/7/2025	DVAX Dynavax Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$33.00 ➝ $31.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $13.00
5/6/2025	BCRX BioCryst Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $13.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $17.00
5/6/2025	BCRX BioCryst Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/2/2025	FOLD Amicus Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$21.00 ➝ $22.00
5/2/2025	FOLD Amicus Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$12.00 ➝ $9.00
4/29/2025	BCRX BioCryst Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$20.00
4/17/2025	DVAX Dynavax Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$12.00 ➝ $10.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCRX BioCryst Pharmaceuticals	$503.49M	4.31	N/A	N/A	($2.22) per share	-4.67
DVAX Dynavax Technologies	$294.62M	4.19	N/A	N/A	$4.81 per share	2.14
FOLD Amicus Therapeutics	$543.14M	3.42	N/A	N/A	$0.63 per share	9.57
LGND Ligand Pharmaceuticals	$181.49M	11.96	$4.61 per share	24.39	$40.39 per share	2.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCRX BioCryst Pharmaceuticals	-$226.54M	-$0.26	N/A	N/A	N/A	-30.01%	N/A	-24.06%	8/4/2025 (Estimated)
DVAX Dynavax Technologies	-$6.39M	-$0.52	57.06	20.96	N/A	9.85%	4.22%	2.67%	8/5/2025 (Estimated)
FOLD Amicus Therapeutics	-$151.58M	-$0.09	N/A	14.02	1.51	-10.62%	12.44%	2.60%	8/14/2025 (Estimated)
LGND Ligand Pharmaceuticals	$52.15M	-$7.12	44.82	30.32	N/A	29.68%	4.95%	4.39%	8/5/2025 (Estimated)

Latest DVAX, BCRX, LGND, and FOLD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	LGND Ligand Pharmaceuticals	$1.23	$1.33	+$0.10	-$2.21	$37.84 million	$45.33 million
5/6/2025	Q1 2025	DVAX Dynavax Technologies	$0.03	-$0.11	-$0.14	-$0.77	$70.01 million	$68.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DVAX Dynavax Technologies	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCRX BioCryst Pharmaceuticals	N/A	2.78	2.73
DVAX Dynavax Technologies	0.33	13.23	12.34
FOLD Amicus Therapeutics	2.01	3.39	2.42
LGND Ligand Pharmaceuticals	N/A	12.49	11.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCRX BioCryst Pharmaceuticals	85.88%
DVAX Dynavax Technologies	96.96%
FOLD Amicus Therapeutics	N/A
LGND Ligand Pharmaceuticals	91.28%

Insider Ownership

Company	Insider Ownership
BCRX BioCryst Pharmaceuticals	4.80%
DVAX Dynavax Technologies	2.98%
FOLD Amicus Therapeutics	2.20%
LGND Ligand Pharmaceuticals	7.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCRX BioCryst Pharmaceuticals	530	209.25 million	197.19 million	Optionable
DVAX Dynavax Technologies	350	120.08 million	127.54 million	Optionable
FOLD Amicus Therapeutics	480	307.93 million	292.23 million	Optionable
LGND Ligand Pharmaceuticals	80	19.29 million	17.78 million	Optionable

DVAX, BCRX, LGND, and FOLD Headlines

Recent News About These Companies

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Sells $57,270.00 in Stock

June 13 at 8:42 AM | insidertrades.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives $146.14 Consensus Target Price from Analysts

June 13 at 1:33 AM | americanbankingnews.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Andrew Reardon Sells 500 Shares

June 12 at 9:01 PM | marketbeat.com

LGND Makes Bullish Cross Above Critical Moving Average

June 11 at 3:36 PM | nasdaq.com

Ligand Announces 2025 Investor Day in New York City

June 11 at 7:00 AM | globenewswire.com

GAMMA Investing LLC Purchases 61,996 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

June 10, 2025 | marketbeat.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of "Buy" from Brokerages

June 10, 2025 | marketbeat.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Bought by Congress Asset Management Co.

June 7, 2025 | marketbeat.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Andrew Reardon Sells 1,000 Shares

June 3, 2025 | marketbeat.com

Andrew Reardon Sells 1,000 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock

June 3, 2025 | insidertrades.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $5.40 Million Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

June 3, 2025 | marketbeat.com

Summit Global Investments Acquires 6,407 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

June 1, 2025 | marketbeat.com

Kings Path Partners LLC Reduces Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

May 31, 2025 | marketbeat.com

Squarepoint Ops LLC Purchases Shares of 16,799 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

May 31, 2025 | marketbeat.com

Bank of America Corp DE Purchases 2,533 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

May 25, 2025 | marketbeat.com

Castleark Management LLC Cuts Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

May 23, 2025 | marketbeat.com

Graham Capital Management L.P. Makes New Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

May 18, 2025 | marketbeat.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Buy" by Brokerages

May 18, 2025 | marketbeat.com

Deutsche Bank AG Purchases 15,160 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

May 16, 2025 | marketbeat.com

Janus Henderson Group PLC Acquires 5,929 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

May 15, 2025 | marketbeat.com

Ligand Pharmaceuticals (NASDAQ:LGND) Downgraded to Sell Rating by StockNews.com

May 15, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DVAX, BCRX, LGND, and FOLD Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

$10.37 -0.03 (-0.29%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$10.40 +0.03 (+0.29%)

As of 06/13/2025 07:55 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Dynavax Technologies NASDAQ:DVAX

$10.27 -0.13 (-1.25%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$10.19 -0.08 (-0.74%)

As of 06/13/2025 07:17 PM Eastern

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Amicus Therapeutics NASDAQ:FOLD

$6.03 -0.14 (-2.27%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$6.03 0.00 (0.00%)

As of 06/13/2025 04:04 PM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Ligand Pharmaceuticals NASDAQ:LGND

$112.50 -1.95 (-1.70%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$112.52 +0.02 (+0.02%)

As of 06/13/2025 06:25 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time